Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trientine dihydrochloride versus trientine tetrahydrochloride pharmacokinetic crossover study in healthy adults
NL-OMON42700Phase 1Active, not recruiting
- Sponsor
- Orphalan
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trientine and trientine tetrahydrochloride in Wilson disease (WD) (2 arms), sponsored by Orphalan. Primary endpoint: Plasma pharmacokinetic profile comparison. Started Jun 2015; status: active, not recruiting.
02
Drugs
trientinetrientine tetrahydrochloride
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NL-OMON42700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42700.